Stay updated on REL-1017 Adjunct in MDD: Efficacy/Safety Clinical Trial
Sign up to get notified when there's something new on the REL-1017 Adjunct in MDD: Efficacy/Safety Clinical Trial page.

Latest updates to the REL-1017 Adjunct in MDD: Efficacy/Safety Clinical Trial page
- Check4 days agoChange DetectedThe RELIANCE-II Phase 3 study record is now displayed, describing REL-1017 as an adjunctive treatment for major depressive disorder and noting that the trial was terminated early after an interim analysis. The record also includes study design, eligibility criteria, locations, outcome measures, and supporting documents.SummaryDifference76%

- Check11 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA site-wide NIH announcement about replacing the term “Artificial Intelligence” with “Super Intelligence” appears above the page. The footer revision label advances from v3.7.1 to v3.7.2, while the study record remains unavailable.SummaryDifference1%

- Check39 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page currently shows a 403 Forbidden error instead of the study details, indicating an access issue that blocks viewing the RELIANCE-II study information.SummaryDifference17%

- Check60 days agoChange DetectedThe page's revision tag changed from v3.6.6 to v3.7.0, indicating a newer release of the page software. This update does not modify the study information or how users interact with the page.SummaryDifference0.0%

Stay in the know with updates to REL-1017 Adjunct in MDD: Efficacy/Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REL-1017 Adjunct in MDD: Efficacy/Safety Clinical Trial page.